Literature DB >> 9488070

Transurethral resection of the prostate vs high-energy thermotherapy of the prostate in patients with benign prostatic hyperplasia: long-term results.

F C D'Ancona1, E A Francisca, W P Witjes, L Welling, F M Debruyne, J J De La Rosette.   

Abstract

OBJECTIVE: To evaluate the outcome and durability of high-energy transurethral microwave thermotherapy (HE-TUMT) in comparison with transurethral resection of the prostate (TURP). PATIENTS AND METHODS: Fifty-two patients with BPH and lower urinary tract symptoms were randomized and treated either by TURP (21 patients; mean prostate volume 45 mL, SD 15) or HE-TUMT (31 patients, mean prostate volume 43 mL, SD 12). Long-term results were obtained at a mean (SD) follow-up of 2.4 (0.5) years.
RESULTS: During the follow-up, the mean symptomatic improvement stabilized at 56% after TUMT and 74% after TURP. The mean maximum urinary flow rate increased by 62% after TUMT and 105% after TURP. Before treatment, 78% of patients in the TURP group were obstructed according to urodynamic investigation and after treatment, 14% remained obstructed. In the TUMT group, 67% of patients were obstructed before treatment and 33% remained so afterward. Six patients (19%) underwent TURP after TUMT (four after 1 year) and two patients were also treated with medication. One patient underwent a bladder neck incision after TURP to treat bladder neck sclerosis. Three patients were not satisfied with the outcome after the additional TURP.
CONCLUSION: Both treatment modalities show good symptomatic and objective results at > 2 years of follow-up. Most re-treatments were performed > or = 1 year after treatment and were based on subjective findings.

Entities:  

Mesh:

Year:  1998        PMID: 9488070     DOI: 10.1046/j.1464-410x.1998.00542.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  14 in total

Review 1.  Benign prostatic hyperplasia.

Authors:  M J Barry; C G Roehrborn
Journal:  BMJ       Date:  2001-11-03

Review 2.  Transurethral microwave thermotherapy in benign prostatic hyperplasia.

Authors:  P Minnee; F M Debruyne; J J de la Rosette
Journal:  Curr Urol Rep       Date:  2000-08       Impact factor: 3.092

Review 3.  Transurethral microwave thermotherapy for the treatment of BPH: still a challenger?

Authors:  T R W Herrmann; A J Gross; D Schultheiss; P M Kaufmann; U Jonas; M Burchardt
Journal:  World J Urol       Date:  2006-06-03       Impact factor: 4.226

4.  Ahead of the curve.

Authors:  David B Nash
Journal:  Popul Health Manag       Date:  2013       Impact factor: 2.459

5.  Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.it.

Authors:  Sebastiano Spatafora; Antonio Casarico; Andrea Fandella; Caterina Galetti; Rodolfo Hurle; Elisa Mazzini; Ciro Niro; Massimo Perachino; Roberto Sanseverino; Giovanni Luigi Pappagallo
Journal:  Ther Adv Urol       Date:  2012-12

6.  Effect of an employer-sponsored health and wellness program on medical cost and utilization.

Authors:  Hangsheng Liu; Katherine M Harris; Sarah Weinberger; Seth Serxner; Soeren Mattke; Ellen Exum
Journal:  Popul Health Manag       Date:  2012-07-23       Impact factor: 2.459

7.  The changing practice of transurethral resection of the prostate.

Authors:  M J Young; M Elmussareh; T Morrison; J R Wilson
Journal:  Ann R Coll Surg Engl       Date:  2018-03-15       Impact factor: 1.891

Review 8.  The long-term cost effectiveness of treatments for benign prostatic hyperplasia.

Authors:  Rachael L DiSantostefano; Andrea K Biddle; John P Lavelle
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 9.  How do transurethral needle ablation of the prostate and transurethral microwave thermotherapy compare with transurethral prostatectomy?

Authors:  Ricardo R Gonzalez; Alexis E Te
Journal:  Curr Urol Rep       Date:  2003-08       Impact factor: 2.862

Review 10.  Long-term treatment outcomes of CoreTherm microwave feedback thermotherapy.

Authors:  Evan R Eisenberg; Gopal H Badlani
Journal:  Curr Urol Rep       Date:  2004-08       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.